Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid TumorsDirk Strumberg, Brian Schwartz, Jeffrey W. Clark et al.|The Oncologist|2007Cited by 418
Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and CapecitabineJavier Cortés, Mary Ann Allison, Dale E. Shuster et al.|Journal of Clinical Oncology|2010Cited by 217
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Bohuslav Melichar, Karl D. Lewis et al.|The Lancet Oncology|2018Cited by 216
Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studiesChris Twelves, Ahmad Awada|Breast Cancer Research and Treatment|2014Cited by 214
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016Christian Dittrich, Rainer Kunstfeld, Michael P. Kosty et al.|ESMO Open|2016Cited by 129